Indication
Hormone receptor positive
4 clinical trials
9 products
1 drug
Clinical trial
A Randomized, Double-blind, Parallel-controlled Phase III Trial Evaluating the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated HR-positive, HER2-negative Advanced Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
FulvestrantProduct
TQB3616Product
PlaceboClinical trial
A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-05-01
Product
MRT-2359Product
Oral MRT-2359Clinical trial
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform TrialStatus: Recruiting, Estimated PCD: 2026-12-30
Product
ALX148Product
Fam-Trastuzumab DeruxtecanProduct
ZanidatamabDrug
TucatinibClinical trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib TrialStatus: Withdrawn, Estimated PCD: 2021-11-17
Product
Vic-trastuzumab duocarmazine